Therefore, further knowledge of key regulatory ncRNAs involved in the simultaneous targeting of many pathways, such as the AR signaling axis and cancer metabolic reprogramming, will provide new insights into the development of precise and efficacious anti-CRPC therapies. Here, AR is linked to cancer.